BACKGROUND Uncontrolled bleeding leads to 40-86% of preventable deaths due to trauma. Use of NovoSeven (rFVIIa) in trauma is promising, although data supporting its utilization are limited. CASE REPORT We report the case of a patient who sustained a penetrating grade V cardiac injury (AAST-OIS) and presented postoperative massive coagulopathic bleeding arrested by the administration of platel...

Background. Recombinant factor VIIa has been in use for some time to control bleeding in persons with hemophilia. In the present study we describe our experience with the use of a commercial form of recombinant factor VIIa, NovoSeven(R) (Novo Nordisk, Denmark), to control perioperative bleeding in the course of total knee replacement on a patient who, though not hemophiliac, had a very low tole...

BACKGROUND Cerebral arteriovenous (AV) malformation causes, due to the increased blood flow through a malformation, a massive intraoperative bleeding complicating, so, surgical treatment. The use of intraoperative blood saving apparatus during surgery and a recombinant factor VII-a (NovoSeven) significantly reduce complications during surgical treatment. CASE REPORT We reported a case of surg...

In This Issue: • NovoSeven • Therapeutic Interchanges Introduction: Recombinant human activated Factor VII (rFVIIa), or NovoSeven, is a hemostatic agent which is structurally similar to human plasma-derived coagulation Factor VIIa. Recombinant FVIIa is currently licensed by the US Food and Drug Administration (FDA) in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX o...

The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors. The FENOC study was designed to test equivalence of the products in th...

The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitorbypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors. The FENOC study was designed to test equivalence of the products in the...

Anaphylaxis is a life-threatening emergency that may be confused with other less serious conditions. The onset of true anaphylaxis typically occurs within minutes following exposure to an offending agent, and it can variably include dyspnea/wheezing, hemodynamic compromise, rash, hives/pruritus, swelling, or gastrointestinal symptoms. absence expected association between exposure(s) classic sym...

Objective: A number of hemophilia A patients who receive clotting factors may develop antibodies (inhibitors) against clotting factors. The immune tolerance induction (ITI) method has proved to be a very costeffective alternative to bypassing agents. Iran’s national health authority is interested in implementing the ITI method for the management of hemophilia patients with inhibitors. The objec...